473 related articles for article (PubMed ID: 17571739)
41. Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.
Barbany G; Höglund M; Simonsson B;
N Engl J Med; 2002 Aug; 347(7):539-40. PubMed ID: 12181416
[No Abstract] [Full Text] [Related]
42. Imatinib. Novartis.
Radford IR
Curr Opin Investig Drugs; 2002 Mar; 3(3):492-9. PubMed ID: 12054102
[TBL] [Abstract][Full Text] [Related]
43. [Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells].
Müller MC; Lahaye T; Hochhaus A
Dtsch Med Wochenschr; 2002 Oct; 127(42):2205-7. PubMed ID: 12397549
[TBL] [Abstract][Full Text] [Related]
44. Imatinib alone and in combination for chronic myeloid leukemia.
Druker BJ
Semin Hematol; 2003 Jan; 40(1):50-8. PubMed ID: 12563611
[TBL] [Abstract][Full Text] [Related]
45. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Sawyers CL
Semin Hematol; 2001 Jul; 38(3 Suppl 8):15-21. PubMed ID: 11526597
[TBL] [Abstract][Full Text] [Related]
46. [STI571 (Glivec)--a new drug for the treatment of chronic myeloid leukemia].
Hasselbalch HC
Ugeskr Laeger; 2002 May; 164(22):2914-7. PubMed ID: 12082821
[TBL] [Abstract][Full Text] [Related]
47. [Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy].
Toga W; Kondo M; Tokoro A
Nihon Yakurigaku Zasshi; 2003 Feb; 121(2):119-28. PubMed ID: 12616857
[TBL] [Abstract][Full Text] [Related]
48. [Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis].
Takahari D; Matsunaga T; Fujimi A; Kikuchi T; Seki R; Tanaka I; Takemoto N; Akiyama T; Sato T; Terui T; Kogawa K; Kato J; Kura T; Maeda T; Niitsu Y
Rinsho Ketsueki; 2002 Oct; 43(10):924-30. PubMed ID: 12462028
[TBL] [Abstract][Full Text] [Related]
49. Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation.
Au WY; Lie AK; Ma SK; Wan TS; Liang R; Chan EC; Kwong YL
Bone Marrow Transplant; 2002 Oct; 30(7):453-7. PubMed ID: 12368958
[TBL] [Abstract][Full Text] [Related]
50. Chronic myelogenous leukaemia--new therapeutic principles.
O'Dwyer ME; Druker BJ
J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
[TBL] [Abstract][Full Text] [Related]
51. Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia.
van Deventer HW; Hall MD; Orlowski RZ; Mitchell BS; Berkowitz LR; Hogan C; Dunphy CH; Koehler J; Shea TC
Am J Hematol; 2002 Nov; 71(3):184-90. PubMed ID: 12410573
[TBL] [Abstract][Full Text] [Related]
52. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
Gambacorti-Passerini C; Zucchetti M; Russo D; Frapolli R; Verga M; Bungaro S; Tornaghi L; Rossi F; Pioltelli P; Pogliani E; Alberti D; Corneo G; D'Incalci M
Clin Cancer Res; 2003 Feb; 9(2):625-32. PubMed ID: 12576428
[TBL] [Abstract][Full Text] [Related]
53. Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia.
Hur M; Song EY; Kang SH; Shin DH; Kim JY; Park SS; Cho HI
Ann Hematol; 2002 Apr; 81(4):219-23. PubMed ID: 11976825
[TBL] [Abstract][Full Text] [Related]
54. ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
Mauro MJ; O'Dwyer ME; Druker BJ
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S77-8. PubMed ID: 11587372
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
Azad NA; Shah ZA; Pandith AA; Khan MS; Rasool R; Rasool J; Aziz SA
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1479-1485. PubMed ID: 29936718
[TBL] [Abstract][Full Text] [Related]
56. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Bumm T; Müller C; Al-Ali HK; Krohn K; Shepherd P; Schmidt E; Leiblein S; Franke C; Hennig E; Friedrich T; Krahl R; Niederwieser D; Deininger MW
Blood; 2003 Mar; 101(5):1941-9. PubMed ID: 12411298
[TBL] [Abstract][Full Text] [Related]
57. Imatinib mesylate.
Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
[No Abstract] [Full Text] [Related]
58. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib.
Meeus P; Demuynck H; Martiat P; Michaux L; Wouters E; Hagemeijer A
Leukemia; 2003 Feb; 17(2):465-7. PubMed ID: 12592350
[No Abstract] [Full Text] [Related]
59. Minimal residual disease in chronic myeloid leukaemia patients.
Hochhaus A
Best Pract Res Clin Haematol; 2002 Mar; 15(1):159-78. PubMed ID: 11987922
[TBL] [Abstract][Full Text] [Related]
60. Management of chronic myeloid leukemia: targets for molecular therapy.
Barnes DJ; Melo JV
Semin Hematol; 2003 Jan; 40(1):34-49. PubMed ID: 12563610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]